VERU Stock Summary and Trading Ideas (Veru | NASDAQ:VERU)

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Veru trades on the NASDAQ stock market under the symbol VERU.

As of January 5, 2026, VERU stock price climbed to $2.29 with 90,402 million shares trading.

VERU has a beta of 0.39, meaning it tends to be less sensitive to market movements. VERU has a correlation of 0.00 to the broad based SPY ETF.

VERU has a market cap of $36.76 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, VERU traded as high as $65.70 and as low as $2.10.

The top ETF exchange traded funds that VERU belongs to (by Net Assets): VTI, VXF, MSSM.

VERU has underperformed the market in the last year with a price return of -68.9% while the SPY ETF gained +17.4%. VERU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.7% and 0.0%, respectively, while the SPY returned +3.1% and +0.4%, respectively.

VERU support price is $2.17 and resistance is $2.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU shares will trade within this expected range on the day.